Program
navenibart
Also written as “Navenibart”, “STAR-0215” and “STAR-0215 (SC)”.
Its studies are mostly in Angioedemas, Hereditary, led by BioCryst Pharmaceuticals.
Furthest: phase 3, since Feb 19, 20255 company-led studies, 3 open or runningNext primary completion: Dec 2026 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| BioCryst Pharmaceuticals | 53 open or running | phase 3since Feb 19, 2025 | Jul 26, 2022 | Dec 2026phase 3 · NCT06842823 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 26, 2022First study: phase 1 study in Angioedemas, HereditaryFirst studyNCT05477160 · 41 enrolled · United States
- Jan 6, 2023Phase 2 study in Angioedemas, HereditaryNCT05695248 · 29 enrolled · United States, Bulgaria, Canada and more
- Aug 17, 2023Phase 2 study in Angioedemas, HereditaryNCT06007677 · 56 enrolled · United States, Bulgaria, Canada and more
- Feb 19, 2025Phase 3 study in Angioedemas, HereditaryNCT06842823 · 157 enrolled · United States, Australia, Austria and more
- Sep 30, 2025Phase 3 study in Angioedemas, HereditaryNCT07204938 · 145 planned · United States, Brazil, Bulgaria and more
Ahead
- Dec 2026Primary completion: phase 3 study in Angioedemas, HereditaryNCT06842823
- Mar 2031Primary completion: phase 2 study in Angioedemas, HereditaryNCT06007677
- Jun 2031Primary completion: phase 3 study in Angioedemas, HereditaryNCT07204938
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07204938Angioedemas, Hereditary · United States, Brazil, Bulgaria and more | 3 | By invitation | Jun 2031 | 145 |
| NCT06842823Angioedemas, Hereditary · United States, Australia, Austria and more | 3 | Active, not recruiting | Dec 2026 | 157 |
| NCT06007677Angioedemas, Hereditary · United States, Bulgaria, Canada and more | 2 | Active, not recruiting | Mar 2031 | 56 |
| NCT05695248Angioedemas, Hereditary · United States, Bulgaria, Canada and more | 2 | Completed | Mar 13, 2025 | 29 |
| NCT05477160Angioedemas, Hereditary · United States | 1 | Completed | Nov 17, 2023 | 41 |
How it is read
Names in the registry
- “navenibart”, 2 entries
- “Navenibart”, 1 entry
- “STAR-0215”, 1 entry
- “STAR-0215 (SC)”, 1 entry
- “STAR-0215 (IV)”, 1 entry
Conditions, from the studies’ own filings
- Angioedemas, Hereditary, 5 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.